Including SGLT2-Inhibitors in the PQA diabetes medication dosing (DOS) measure may improve identification of high-risk patients

Background: Excessive dosages of oral diabetes medications do not have better efficacy and can cause adverse drug events. The DOS measure identifies excessive dosing of biguanides, sulfonylureas , thiazolidinediones , and dipeptidyl peptidase-4 inhibitors. In 2012, sodium-glucose co-transporter 2 inhibitors (SGLT2-i), a new oral class with documented cardiovascular benefit, were introduced. To remain relevant, it is important to consider how the exclusion of this class affects the current DOS measure.

Source: Research in Social and Administrative Pharmacy - May 1, 2018 Category: Pharmaceuticals Authors: Suji Xie, Dhritiman Mukherjee, Jennifer Naples, Rosenie Thelus, Erik Defreitas, Adrian Kress Source Type: research